We are live on
!
Find out more
TECP
Trails Edge Capital Partners Portfolio holdings
AUM
$630M
This Fund
S&P 500
This Quarter
Est. Return
+17.35%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$437M
AUM Growth
+$31.8M
(+7.9%)
Cap. Flow
+$934K
Cap. Flow
% of AUM
0.21%
Top 10 Holdings %
Top 10 Hldgs %
62.79%
Holding
35
New
12
Increased
4
Reduced
7
Closed
8
Avg Time Held Equity + Options
0.6
quarters
Top 10 Avg Time Held Equity + Options
0.7
quarters
Top 20 Avg Time Held Equity + Options
0.6
quarters
Avg Time Held Equity only
0.6
quarters
Top 10 Avg Time Held Equity only
0.7
quarters
Top 20 Avg Time Held Equity only
0.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mirum Pharmaceuticals
MIRM
|
+$28.4M |
| 2 |
Revolution Medicines
RVMD
|
+$24.7M |
| 3 |
Cytokinetics
CYTK
|
+$19.1M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
+$15.2M |
| 5 |
4D Molecular Therapeutics
FDMT
|
+$11.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Acadia Pharmaceuticals
ACAD
|
+$37.9M |
| 2 |
Tyra Biosciences
TYRA
|
+$18.4M |
| 3 |
Amicus Therapeutics
FOLD
|
+$14.9M |
| 4 |
Apogee Therapeutics
APGE
|
+$14.5M |
| 5 |
Definium Therapeutics
DFTX
|
+$14.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.34% |
| 2 | Miscellaneous | 2.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Vaxcyte
PCVX
$10.6B
| $38.5M | 8.82% |
662,470
-75,000
| -10% | -$4.07M |
2025 Q4
1 quarter
|
|
|
2
Definium Therapeutics
DFTX
$4.96B
| $32.9M | 7.53% |
1,738,110
-830,000
| -32% | -$14.1M |
2025 Q4
1 quarter
|
|
3
LB Pharmaceuticals
LBRX
$1.2B
| $32.5M | 7.45% |
1,319,362
-76,246
| -5% | -$1.76M |
2025 Q4
1 quarter
|
|
|
4
Mirum Pharmaceuticals
MIRM
$5.58B
| $30.8M | 7.05% |
333,312
+301,450
| +946% | +$28.4M |
2025 Q4
1 quarter
|
|
5
Nurix Therapeutics
NRIX
$2.32B
| $27M | 6.19% |
1,743,220
| – | – |
2025 Q4
1 quarter
|
|
6
Xenon Pharmaceuticals
XENE
$3.53B
| $25.6M | 5.86% |
440,000
-157,092
| -26% | -$7.24M |
2025 Q4
1 quarter
|
|
|
7
Revolution Medicines
RVMD
$40.7B
| $23.8M | 5.46% |
+245,000
| New | +$24.7M |
2026 Q1
0 quarters
|
|
8
Arcus Biosciences
RCUS
$3.11B
| $22.6M | 5.19% |
1,047,935
+131,622
| +14% | +$2.84M |
2025 Q4
1 quarter
|
|
9
Immunocore
IMCR
$1.51B
| $20.6M | 4.71% |
682,597
| – | – |
2025 Q4
1 quarter
|
|
|
10
Cytokinetics
CYTK
$8.75B
| $19.8M | 4.53% |
+300,000
| New | +$19.1M |
2026 Q1
0 quarters
|
|
|
11
Syndax Pharmaceuticals
SNDX
$1.52B
| $16.4M | 3.76% |
+701,821
| New | +$15.2M |
2026 Q1
0 quarters
|
|
12
Neurogene
NGNE
$528M
| $15.8M | 3.62% |
782,787
-2,213
| -0.3% | -$42.9K |
2025 Q4
1 quarter
|
|
13
Inventiva
IVA
$747M
| $14.8M | 3.38% |
2,657,997
| – | – |
2025 Q4
1 quarter
|
|
14
Inhibikase Therapeutics
IKT
$275M
| $13.5M | 3.1% |
8,057,345
+1,879,221
| +30% | +$3.34M |
2025 Q4
1 quarter
|
|
|
15
4D Molecular Therapeutics
FDMT
$736M
| $12.1M | 2.78% |
+1,302,917
| New | +$11.3M |
2026 Q1
0 quarters
|
|
|
16
PUT
Xenon Pharmaceuticals
XENE
$3.53B
| $11.6M | 2.66% |
+200,000
| New | +$9.22M |
2026 Q1
0 quarters
|
|
17
X4 Pharmaceuticals
XFOR
$289M
| $10.6M | 2.43% |
2,571,478
| – | – |
2025 Q4
1 quarter
|
|
18
Immunovant
IMVT
$6.29B
| $10.3M | 2.36% |
414,054
+173,889
| +72% | +$4.5M |
2025 Q4
1 quarter
|
|
19
Design Therapeutics
DSGN
$729M
| $9.07M | 2.08% |
+852,013
| New | +$8.62M |
2026 Q1
0 quarters
|
|
20
CAMP4 Therapeutics
CAMP
$237M
| $8.55M | 1.96% |
1,939,563
-44,423
| -2% | -$211K |
2025 Q4
1 quarter
|
|
21
Minerva Neurosciences
NERV
$152M
| $8.55M | 1.96% |
+1,419,000
| New | +$8.14M |
2026 Q1
0 quarters
|
|
22
ProMIS Neurosciences
PMN
$86.2M
| $7.08M | 1.62% |
+557,103
| New | +$8.31M |
2026 Q1
0 quarters
|
|
23
Sol-Gel Technologies
SLGL
$235M
| $6.77M | 1.55% |
+85,496
| New | +$6.17M |
2026 Q1
0 quarters
|
|
24
Century Therapeutics
IPSC
$266M
| $5.54M | 1.27% |
+2,449,993
| New | +$5.15M |
2026 Q1
0 quarters
|
|
25
vTv Therapeutics
VTVT
$123M
| $5.54M | 1.27% |
139,578
-91,422
| -40% | -$3.32M |
2025 Q4
1 quarter
|
|
Similar funds
SJIC
SFO
PPC
ACGA
FAM
MC
GPTE
KNW
Trails Edge Capital Partners's Q1 2026 Portfolio in Review
As of Q1 2026, Trails Edge Capital Partners held 35 positions worth $437M, up 7.9% from $405M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Trails Edge Capital Partners's Q1 2026 filing shows 12 new, 4 increased, 7 reduced and 8 closed positions. Its largest new stake was Revolution Medicines: 245,000 shares worth $23.8M. The largest sale was Acadia Pharmaceuticals, an estimated $37.9M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
- Trails Edge Capital Partners's largest Q1 2026 buy was Revolution Medicines: 245,000 shares worth $23.8M.
- Trails Edge Capital Partners added most to Mirum Pharmaceuticals in Q1 2026, an estimated $28.4M increase.
- Trails Edge Capital Partners's biggest Q1 2026 reduction was Definium Therapeutics, cutting an estimated $14.1M.
- Trails Edge Capital Partners fully exited Acadia Pharmaceuticals in Q1 2026, selling an estimated $37.9M.
- Trails Edge Capital Partners's ten largest holdings make up 63% of its $437M portfolio in Q1 2026.
- Trails Edge Capital Partners opened 12 new positions and closed 8 in Q1 2026.
- Trails Edge Capital Partners's portfolio value rose 7.9% quarter-over-quarter to $437M.
Based on Trails Edge Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.